Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Terlipressin	199
Overall Study	STARTED	Placebo	101
Overall Study	Intent to Treat (ITT)	Terlipressin	199
Overall Study	Intent to Treat (ITT)	Placebo	101
Overall Study	Safety Analysis Set (SAS)	Terlipressin	200
Overall Study	Safety Analysis Set (SAS)	Placebo	99
Overall Study	Systemic Inflammatory Response Syndrome (SIRS) Subgroup	Terlipressin	84
Overall Study	Systemic Inflammatory Response Syndrome (SIRS) Subgroup	Placebo	48
Overall Study	COMPLETED	Terlipressin	87
Overall Study	COMPLETED	Placebo	52
Overall Study	NOT COMPLETED	Terlipressin	112
Overall Study	NOT COMPLETED	Placebo	49

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02770716/flow